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Results

Introduction:
Prevalence of Diabetes Mellitus is four to five times higher among people with schizophrenia than the general population (1). Those, who suffer from both diabetes and schizophrenia, have 3-4 fold higher overall mortality rates than general population, and at least one-third of those deaths can be attributed to diabetes (2). Diabetes contributes to excessive cardiovascular deaths and more than 20 years of reduced life expectancy in people with schizophrenia (3,4). Young people with schizophrenia, aged less than 40 years, are at high risk (5) for early-onset type-2 diabetes that is a rapidly progressing severe disease subtype with increased risks for microvascular and macrovascular complications (4,6-8).
Studies from the pre-neuroleptic era (9) have reported increased prevalence of diabetes, impaired glucose tolerance, and increased insulin resistance in people with schizophrenia (10) (11) (12) . Abnormal glucose tolerance is more prevalent in antipsychotic naïve people with schizophrenia than among healthy controls, and this association is independent of the effects of Body Mass Index and of poor health habits (13) (14) (15) . Moreover, increased prevalence of diabetes among the first-degree relatives of people with schizophrenia indicates a potential genetic link between schizophrenia and diabetes (16, 17) . TCF7L2 and IGF2BP2, two of the most replicated susceptibility genes for type-2 diabetes, have been associated with schizophrenia (18) (19) (20) .
Furthermore, linkage studies, genetic association studies, and pathway analyses have supported shared genetic risks between these two disorders (21-23).
As soon as chlorpromazine was introduced in 1952, there were several reports of its association with diabetes and impaired glucose tolerance (10 
Statistical analyses:
We calculated age-specific and gender-specific incidence rates of diabetes and their 95% confidence intervals (95% CI). In order to investigate the endogenous risk for diabetes, we used Cox proportional hazards regression models to compute adjusted hazard ratio for diabetes in antipsychotic naïve people with schizophrenia, compared with antipsychotic naïve people without schizophrenia. Follow-up began on the date of birth and ended on the date of diabetes diagnosis, first prescription of antipsychotics, emigration, death, or on 01/01/2013. The first registered diagnosis of schizophrenia during follow-up was included as a time-dependent p<0.001).
Incidence of diabetes:
A total of 14,118 (0.52%) people developed diabetes in this cohort (See eFigure1 in the supplemental data). Age-specific incidence rates of diabetes in people with and without schizophrenia are presented in Table 2 (See eFigure 2 in the supplemental data). Gender- Endogenous risk for diabetes: Among the people, who have not been exposed to any antipsychotics, 12,976 (0.5%) without schizophrenia, and 11 (0.9%) with schizophrenia developed incident diabetes during our follow-up. 
Sensitivity analyses:
We conducted sensitivity analyses, limited to potential type-2 diabetes diagnoses in this cohort (n=5,488; 0.20%), and confirmed earlier findings of higher rates of diabetes in antipsychotic naive schizophrenia compared with the general population (Adjusted hazard ratio=4.71; 95% CI 2.60-8.51), and increased rate of diabetes after starting any antipsychotic drug in people with schizophrenia (Adjusted hazard ratio=3.79; 95% CI 1.97-7.26) without statistically significant differences between first-generation and second-generation antipsychotics (χ 2 =0.04; p=0.85) (See eAppendix-2,3,5 in the supplemental data). We performed more sensitivity analyses after excluding 19 people, who developed diabetes more than 12 months after the last prescription of any antipsychotic, to distinguish direct antipsychotic effects from the potential effects of antipsychotic-related weight-gain. Results of this sensitivity analysis also corroborated our earlier findings. Antipsychotic-related risk for diabetes after starting any 
Discussion:
This nation-wide population-based cohort study has revealed an increased endogenous risk for diabetes in antipsychotic naïve people with schizophrenia compared with people without schizophrenia. It has confirmed the antipsychotic-related risks for diabetes in people with schizophrenia after adjusting for potential confounders including family history of diabetes.
Moreover, it has added evidence that first-line treatments with either first-generation or secondgeneration antipsychotics do not significantly differ on their antipsychotic-related risks for diabetes. Furthermore, it has documented that the antipsychotic-related rates of diabetes in people with schizophrenia, who had received other antipsychotics, further increased four-fold after starting clozapine. Strengths of this study include the hitherto largest sample size, the hitherto longest follow-up, studying antipsychotic naive people with schizophrenia, focus on An important limitation of our study is that we could not reliably distinguish between type-1 and type-2 diabetes. Misclassification between type-1 and type-2 diabetes is likely, and a complete classification is not possible on the basis of the information available in Danish national registers (47, 51) . We can only distinguish between type-1 and type-2 diabetes on the basis of ICD codes and insulin-only therapy potentially indicating type-1 diabetes. Moreover, people with schizophrenia are often diagnosed with ICD-10 codes for unspecified diabetes.
However, sensitivity analyses, limited to potential type-2 diabetes, corroborated our findings. A substantial proportion of incident diabetes in young people with schizophrenia is expected to be early-onset type-2 diabetes (52) . Early-onset type-2 diabetes can be a distinct severe rapidly progressing disease phenotype (4,7,8). This may limit generalisability of our findings to older people with schizophrenia, but may emphasise their clinical importance. Besides, the possibility of increased surveillance of people with schizophrenia by the health services, and consequent surveillance bias may explain the increased incidence of diabetes in antipsychotic-naive schizophrenia. However, prior evidence suggests that the proportion of undiagnosed diabetes may be higher among people with schizophrenia than the general population (53, 54) . Moreover, studying a relatively homogenous and predominantly Caucasian population from a single country may limit generalisability of our findings, but this should strengthen their internal validity (55). Other limitations of this study include lack of data on other potential confounders, such as obesity, dyslipidaemia, smoking, other substance abuse, diet, and sedentary life style, lack of data on drugs dispensed within hospitals in Danish National Prescription Registry, and grouping diverse antipsychotics together during our analyses. Controlling for all potential P e e r R e v i e w O n l y 3 
